You are here

Generic Version of Agrylin Cleared by FDA

WOODCLIFF LAKE, N.J., April 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its wholly-owned subsidiary, Barr Laboratories, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Shire Pharmaceutical Group's Agrylin(R) (Anagrelide Hydrochloride) Capsules, 0.5 mg and 1 mg. The Company anticipates launching its generic product immediately.

Anagrelide Hydrochloride capsules are approved for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. Anagrelide Hydrochloride capsules had annual sales of approximately $107 million, based on IMS data for the twelve months ended February 2005.

Source: Barr Pharmaceuticals, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs